摘要:
The present invention relates to progesterone receptor antagonists of general formula I: in which R1 can be a hydrogen atom and R2 a hydroxyl group or R1 and R2 together can be an oxo group.
摘要:
The invention relates to 3,5-dihydroxy-2,2-dimethyl-valeronitriles for the synthesis of epothilones and epothilone derivatives and process for the production of these new intermediate products in the synthesis and the use for the production of epothilones or epothilone derivatives.
摘要:
The invention relates to a new synthetic process for the production of key intermediates useful in the synthesis of epothilones or epothilone derivatives, to certain compounds used to produce these key intermediates and to a process to produce said compounds. The intermediates used are represented by formulae II and III, wherein R is selected from H, alkyl and substituded alkyl and X1 is an oxygen protecting group.
摘要:
The present invention relates to 11β-fluoro-3-acetoxyestra-3,5-diene-17-on as suitable intermediate preparation for the production of 11-fluoro-sbustituted steroids and to the method for the production thereof. For this purpose, 11α-hydroxyestr-4-en-3,17-dion is reacted in an organic non-protic solvent with 1 to 3 equivalents of n-nonafluorobutanesulfonyl fluoride and 3 to 5 equivalents of diazabicycloundecene (DBU) at -40 to -20°C and, after an aqueous processing step, 5 to 10 equivalents of acetic acid anhydride and 0.01 to 1 equivalent of a strong acid are added. The desired product precipitates immediately from the reaction solution and is obtained in a very high purity by filtration. The method is characterized by a very high yield, avoidance of a chromatographic purification of the product, a lower amount of waste, and considerably increased process throughput. The method according to the invention is thus particularly suitable for the production of 11β-fluoro-3-acetoxyestra-3,5-diene-17-on on a large technical scale.
摘要:
The invention relates to crystalline lithium complexes of N-(1-hydroxymethyl-2,3-dihydroxypropyl)-1,4,7-triscarboxymethyl-1,4,7,10 tetraazacyclododecane of formula (I), wherein: all of the three X's represent n lithium ions and m hydrogen atoms, whereby n and m each represent numbers from 0 to 3, preferably from 0.8 to 2.2, and the sum of n and m equals 3, and; Y represents chloride and bromide. The invention relates to the preparation of the inventive complexes and to production of the salt-free gadolinium complex of N-(1-hydroxymethyl-2,3-dihydroxypropyl)-1,4,7-triscarboxymethyl-1,4,7,10 tetraazacyclododecane from the same without involving the use of ion exchangers.
摘要:
The present invention relates to optically active heteroaromatic β -hydroxy esters of formula (I) useful in the synthesis of epothilone derivatives, to beta-keto esters of formula (IV) used to produce these intermediates by means of an asymmetric hydrogenation with a chiral metal catalyst or microbiological or enzymatic reduction, as well as to processes for their production (I), wherein: A is a bicyclic heteroaromatic residue of formula (A), wherein “heteroaromatic” stands for a 5-or 6-membered heteroaromatic ring having up to 2 heteroatoms selected from oxygen, nitrogen or sulphur, which is optionally substituted with one or two substituents selected from alkyl, optionally protected hydroxyalkyl, halo-alkyl, halogen or CN, and R is a straight-chain or branched, optionally saturated alkyl chain, which optionally contains 1-3 oxygen atoms; phenyl: cyclohexyl; or benzyl residue (IV).
摘要:
The invention relates to 17 alpha -alkyl-17 beta -oxy-estra-1,3,5(10)-trienes having an anti-oestrogen action, of general formula (I). The invention also relates to 17-oxo-estra-1,3,5(10)-trienes and 17 beta -hydroxy-estra-1,3,5(10)-trienes as intermediates for producing the inventive estratrienes. The invention further relates to the use of 17 alpha -alkyl-17 beta -oxy-estratrienes for the production of medicaments and pharmaceutical preparations containing at least one 17 alpha -alkyl-17 beta -oxy-estratriene and at least one pharmaceutically acceptable carrier.